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Human papillomavirus (HPV) is recognised as necessary for the development of cervical cancer. An age-stratified random sample
of 1013 women, aged 25–70 years, participating in the organised cervical screening programme in Turin, Italy was tested for 36 HPV
types using polymerase chain reaction (PCR) with the general primers GP5+/GP6+. The overall HPV prevalence was 8.8%. High-
risk types were found in 7.1% of women and multiple infections in 1.1%. HPV-16 was the most common type (32.6% of HPV-
positive women). HPV prevalence (any type) was 13–14% at ages 25–39 years, 11.5% at age 40–44 years, and approximately 5%
among older women. After age-adjustment, HPV prevalence was significantly increased in single vs married, (Odds Ratio
(OR) = 2.23; 95% Confidence Interval (CI): 1.28–3.89) and decreased in parous vs nulliparous women (OR = 0.49; 95% CI: 0.31–
0.78). However, the association with marital status and parity was restricted to women less than 45 years of age. In conclusion, over-
all, the female population of Turin showed an HPV prevalence that is intermediate compared with worldwide levels.
 2004 Elsevier Ltd. All rights reserved.
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Infection with high-risk types of human papillomavi-
rus (HPV) is found in virtually all cases of cervical can-
cer [1] and is considered a necessary factor in invasive
cervical cancer [1,2]. This finding has stimulated interest
in HPV DNA testing as a means of screening for cervi-
cal cancer [3] and in the development of prophylactic
and therapeutic vaccines against HPV [4].0959-8049/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2004.07.005
* Corresponding author. Tel.: +390116333850; fax:
+390116333861.
E-mail address: guglielmo.ronco@cpo.it (G. Ronco).Before vaccines or HPV-based cervical screening can
be introduced at a population level, information is
needed on the age- and type-specific prevalence of
HPV infection in representative samples of the female
population. Few such studies have been conducted [5–
13], particularly in Southern Europe [14,15], and no
large population-based survey of the prevalence of
type-specific HPV is available for Italy.
In Turin, an organised screening programme for cer-
vical cancer has been active for many years. All female
residents aged 25–64 years are invited to have a Papa-
nicolau (Pap) smear every 3 years, independent of their
history of spontaneous screening [16]. Comparisons of
the socio-demographic features of the women who do
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shown any substantial differences [17] and, therefore,
screening participants can be considered to be a reason-
ably representative sample of the Turin population.
We estimated the prevalence of cervical HPV infec-
tion in this population by means of a cross-sectional
study, one of a number of HPV prevalence surveys being
conducted by International Agency for Research on
Cancer (IARC) on different continents.2. Methods
2.1. Study population
Cervical cell samples were obtained from all women
who came after invitation (between April and June
2002) for cytological analysis within the framework of
the Turin organised cervical screening programme during
a pilot project on the use of liquid-based cytology. Of
these women, 6556 (89.4%) agreed to participate in the
present study and gave their written informed consent.
A random sample of stored specimens was selected,
excluding those from 559 women who (a) were pregnant,
(b) had undergone a hysterectomy or (c) whose smear
was unsatisfactory (e.g., lack of endocervical cells). Con-
versely, the presence of cytological abnormalities was
not considered a basis for exclusion. We sampled
approximately 100 women in each 5-year age group be-
tween 25–29 years and 65–70 years. Each age group in-
cluded a proportion of women who had not been
screened previously, and this reflected the proportions
of women in the Turin population in the same age
groups who had previously been estimated never to have
been screened [16]. All women aged over 64 years who
participated were included in our sample. Overall, sam-
ples from 1025 women were analysed.
2.2. Human papillomavirus DNA detection and typing
Cervical cells were obtained with a Cervex brush and
placed in Cytorich medium. After one thin-layer slide
had been prepared, the remaining material was centri-
fuged at 600 rotations per minute (rpm) for 5 min.
The preserving liquid was then discarded, and the pellet
was re-diluted in 150 ll of Cytorich medium and trans-
ferred to Eppendorf tubes, which were stored at 20 C.
HPV DNA was detected by polymerase chain reac-
tion (PCR) with the consensus primer set GP5+/
GP6+, which targets a highly conserved fragment of
the L1 open-reading frame. Specific HPV groups were
detected with high-risk and low-risk cocktail probes in
a PCR–immunoassay procedure. Final HPV typing
was performed with a non-radioactive reverse line blot
system with specific oligoprobes for the most frequent
HPV types.Aliquots of 100 ll of each specimen were boiled for
10 min at 100 C and immediately cooled on ice. The
first aliquot of 10 ll of a given extract was screened with
a b-globin PCR, to check the DNA quality and compe-
tence; a second 10 ll aliquot was used for HPV DNA
detection and typing. The b-globin gene amplification
was positive in 1013/1025 samples (98.8%). The 12 b-
globin-negative samples were excluded from the HPV
analysis.
In the b-globin-positive samples, HPV DNA was de-
tected using the GP5+/GP6+ PCR assay, which allows
identification of a broad spectrum of genital HPV
types [18]. PCR positivity was assessed by hybridisa-
tion of PCR products in an enzyme immunoassay
(EIA) using two HPV oligoprobe cocktails that to-
gether contain the following 36 HPV types: 6, 11, 16,
18, 26, 31, 33–35, 39, 40, 42–45, 51–59, 61, 66, 68,
70, 71, 72, 73, 81, 82, 83, 84, and CP6108 [6,19]. The
sensitivity and specificity of EIA detection were deter-
mined previously using dilution lines of cloned HPVs
or cervical smears in which these types were identified
in earlier studies [6,20].
Final genotyping for the individual HPV types was
achieved with a recently described reverse line blot
hybridisation assay [19] with specific probes. The system
is based on a miniblotter (MN45, Immunetics, Cam-
bridge, MA, USA) that spots up to 37 different oligo-
probes which are covalently bound to negatively
charged membranes in parallel lines. Forty-two biotinyl-
ated products from the GP5+/GP6+ PCR were spotted
in lines perpendicular to those containing the oligo-
probes. Hybridisation was performed for 1 h at 42 C
in the miniblotter and hybrids were visualised by a per-
oxidase-labelled streptavidin conjugate that interacts
with biotinylated DNA. Final detection was done by en-
hanced chemiluminescence (ECL, Amersham, Bucks,
England). HPV types were classified as high-risk and
low-risk according to Mun˜oz and colleagues [21]. Spe-
cial precautions were taken to minimise false-positive re-
sults in the PCR, as described in detail elsewhere [22].
2.3. Explanatory variables
The information collected from each woman during
the gynaecological visit included parity, concomitant
pregnancy, previous gynaecological treatments and cur-
rent use of oral contraceptives. The socio-demographic
characteristics of the women and, for married women,
of their husbands, were determined by means of record
linkage with data in the Turin Population Registry,
which is virtually complete and highly reliable. Addi-
tional information, such as the occupations of women
and their husbands, was obtained through linkage with
the records of the 1991 population census using a previ-
ously validated method [23]. The latter record linkage
was possible for 84% of our study women.
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Odds ratios (ORs) for positivity for HPV were com-
puted by means of unconditional logistic regression
models. The approximate 95% Confidence Intervals
(CIs) of the ORs were computed from Wald-type stand-
ard errors. In selected cases, a test of the overall effect of
categorical variables was computed by a likelihood ratio
v2 comparing models with and without the considered
variables. All P values are two-sided. The ORs were ad-
justed for age (5-year groups) and for additional varia-
bles, as specified.3. Results
3.1. Human papillomavirus prevalence and distribution of
types
HPV infection was found in 89 of the 1013 women eli-
gible for the DNA analysis (8.8%; 95% CI: 7.0–10.5). The
prevalence in the age range 25–70 years was 8.8% when
standardised by age on the basis of the Turin population
in 1998 and 9.5% when standardised on the basis of the
world standard population. HPV DNA was found in
78 of the 997 women with normal cytological specimens
(7.8%) and in 11/16 (68.8%) of those with abnormal
cytology. These included 2 cases with histologically-con-
firmed cervical intraepithelial neoplasia (CIN) grade III
and 3 cases with histologically confirmed CIN I. All were
positive for high-risk HPV types (Table 1).
We identified a total of 103 infections from 24 differ-
ent HPV types, and 11 women (12.4% of those infected)
carried multiple types. High-risk types (Table 1) were
found in 72 women (7.1% of study women and 80.9%
of infected women). HPV 16 was by far the most com-
mon type (29 women infected, alone or in conjunction
with other types), followed by HPV 66 (10 women),
HPV 45 (7 women) and HPV 31 (6 women). Type 18
was found in only one woman. Some 17 women were in-
fected with low-risk types only (1.7% of study women,
19.1% of infected women). HPV 42 (8 cases) and HPV
81 (4 cases) were the most common low-risk types.
The prevalence of HPV (any type) was 13–14%
among women aged 25–39 years, 11.5% in those aged
40–44 years (Fig. 1 and Table 2) and only approximately
5% in the older age groups. Despite some fluctuations
from one group to another, the downwards trend in
HPV prevalence was compatible with a linear decrease:
the linear effect by single year was statistically significant
ðv21df ¼ 15:29; P < 0:0001Þ and adding age in 5-year
groups increased the fit only marginally (likelihood ratio
v28df ¼ 6:25; 0:75 < P < 0:50). Although low-risk types
were rarer than high-risk types at any age, the age pat-
tern was somewhat different and prevalence of low-risk
types reached a small peak at 40–44 years (3.8%).3.2. Determinants of the prevalence of human papilloma-
virus infection
After adjustment for age, the prevalence of HPV was
slightly increased in women with the lowest (no recog-
nised diploma) or highest (university degree) educa-
tional levels in comparison with a primary school
degree. However, none of these differences attained sta-
tistical significance (Table 2). Place of birth (South or
North of Italy) was unrelated to HPV prevalence (data
not shown). Prevalence was significantly increased
among the few women who reported not having a toilet
at home (OR = 3.51; 95% CI: 1.07–11.51).
The prevalence of HPV slightly increased among wo-
men whose husbands had no educational degree (Table
2), but was not related to the husbands age nor to the
age difference between spouses (data not shown).
An OR of 2.23 (95% CI: 1.28–3.89) was found for sin-
gle (never married) compared with married women.
HPV was detected significantly less frequently in parous
than in nulliparous women (OR = 0.49; 95% CI: 0.31–
0.78), but among parous women, the number of children
was not significantly associated with HPV positivity
(Table 2). Age at marriage was unrelated to HPV prev-
alence (Table 2). HPV infection was, however, inversely
associated with the age at first birth (OR for ageP 30 vs
<20 = 0.28; 95% CI: 0.10–0.84), and this trend persisted
after adjustment for education, occupation and parity.
Current use of oral contraceptives was associated with
an OR of 1.36 (95% CI: 0.73–2.52).
3.3. Age trend by marital status and parity
In order to further elucidate the combined effect of
age, marital status and nulliparity, which were the
strongest correlates of HPV infection in this study, we
evaluated HPV prevalence by age separately in single
women (never married), nulliparous married women
and parous married women (Table 3). At age 25–44
years, single women had a higher prevalence of HPV
than parous married women (OR = 3.24; 95% CI: 1.61–
6.51), while the prevalence of HPV among nulliparous
married women was intermediate. The prevalence of
HPV was similar among all strata at P 45 years of age.4. Discussion
The prevalence of HPV DNA in our study in Turin
was 8.8% in women aged 25–70 years, and decreased
to 7.8% after exclusion of women with abnormal cervi-
cal cytological findings. The peak prevalence was
13.9%, in the age group 35–39 years (i.e., later than in
most populations studied so far). A similar HPV preva-
lence was found in women aged 24–64 years in a case-
control study conducted within the cervical screening
Table 1
Human papillomavirus (HPV) types detected in 1013 women in Turin, Italy, 2002
HPV Cytological finding
Normala Abnormalb All
No. of women (% of all women) No. of women (% of all women) No. of women (% of all women)
Negative 919 5e 924
Positive 78 (7.8) 11 (68.8) 89 (8.8)
High-risk typesc 61 (6.1) 11 (68.8) 72 (7.1)
Low-risk typesd 17 (1.7) 0 17 (1.7)
6 1 (0.1) 0 1 (0.1)
11 2 (0.2) 0 2 (0.2)
16 24 (2.4) 2f (12.5) 26 (2.6)
18 1 (0.1) 0 1 (0.1)
31 2 (0.2) 3e (18.8) 5 (0.5)
33 1 (0.1) 1g (6.3) 2 (0.2)
35 1 (0.1) 0 1 (0.1)
39 3 (0.3) 0 3 (0.3)
42 4 (0.4) 0 4 (0.4)
43 1 (0.1) 0 1 (0.1)
45 5 (0.5) 1g (6.3) 6 (0.6)
51 1 (0.1) 1e (6.3) 2 (0.2)
52 2 (0.2) 0 2 (0.2)
54 2 (0.2) 0 2 (0.2)
56 2 (0.2) 0 2 (0.2)
58 3 (0.3) 0 3 (0.3)
61 1 (0.1) 0 1 (0.1)
66 6 (0.6) 0 6 (0.6)
68 1 (0.1) 1e (6.3) 2 (0.2)
70 1 (0.1) 0 1 (0.1)
72 2 (0.2) 0 2 (0.2)
81 3 (0.3) 0 3 (0.3)
Total single 69 (6.9) 9 (56.3) 78 (7.7)
16,42 2 (0.2) 0 2 (0.2)
16,66 1 (0.1) 0 1 (0.1)
31,53 1 (0.1) 0 1 (0.1)
33,42, 53,58 0 1g (6.3) 1 (0.1)
42,66 0 1e (6.3) 1 (0.1)
45,56 1 (0.1) 0 1 (0.1)
51,59,66 1 (0.1) 0 1 (0.1)
52,68 1 (0.1) 0 1 (0.1)
56,81 1 (0.1) 0 1 (0.1)
58,66 1 (0.1) 0 1 (0.1)
Total multiple 9 (0.9) 2 (12.5) 11 (1.1)
Total 997 16 1013
a Includes benign cellular changes.
b Atypical squamous cells of undetermined significance (7 cases) or more severe cytology.
c Alone or with low-risk types.
d In the absence of high-risk types.
e No histologically-confirmed cervical intraepithelial neoplasia (CIN).
f Histologically confirmed CIN 3.
g Histologically confirmed CIN 1.
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any of six high-risk HPV types (HPV 16, 18, 31, 33,
52 and 58) was found in 5.1% of 332 archival smears
from women without CIN II, or more severe lesions
[24]. The overall prevalence of HPV DNA among 3305
cytologically-negative women aged 15–70 years who
participated in cervical screening in The Netherlands
was 4.6%, and the rate peaked at 20% at age 25–29 years
[6]. The incidence of invasive cervical cancer in that
country in 1993–1997 (world-standardised rate 6.6/100 000) [25] was also similar to that in Turin (6.8/
100 000).The rate of detection of HPV DNA in a ran-
dom population sample of 1000 women aged 20–29
years with normal cytological appearance in Copenha-
gen, Denmark, was 15% [26], which is similar to the
prevalence of 13% that we found in Turin among wo-
men aged 25–29 years. The prevalence of HPV among
878 women aged 20–49 years with normal cervical
smears who were sampled randomly from general prac-
tice lists in Ontario, Canada, was 13%, with a peak of
Fig. 1. Prevalence of human papillomavirus infection by age group in Turin, Italy, 2002.
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HPV prevalence was observed in other southern Euro-
pean countries, like Spain (3%) [15] and Greece (2.5%)
[14].
Community-based surveys on continents other than
Europe and North America have shown a broad range
of prevalence, from 2% in Hanoi, Vietnam [10], to
26% in Ibadan, Nigeria [13], among women aged 15–
74 years.
Most of the cases of cervical infection with HPV in
our study were single infections with high-risk types.
The frequency of multiple infections was lower than in
other populations [6], especially Latin American ones
in whom HPV infection is substantially more frequent
[5,11]. In our study, half of the infections were due to
types 16, 66, 45 and 31, in decreasing order. The fre-
quency of HPV 16 was high (32.6% of HPV-positive wo-
men), while type 18 was almost absent. Low-risk types
were rare, but, as observed in other areas [5,6,12], they
represented a larger proportion of infections in mid-
dle-aged women than in young women.
We found a limited effect of education and occupa-
tion on the prevalence of HPV, although both low and
very high social classes appeared to be related to a
slightly increased risk. A direct association between
HPV prevalence and years of education was observed
in a few studies, although the finding was not always sta-
tistically significant [9,10,12,27].
Current use of oral contraceptives was not associated
with an increased risk for HPV infection in our study,
but we had no information on the duration of suchuse. An association between HPV DNA and oral con-
traceptive use, after adjustment for sexual habits, was
reported in some studies [7,10,26,28,29], but not in oth-
ers [8,27,30,31], and whether oral contraceptives affect
the incidence or prevalence of HPV infection remains
unclear [32].
Together with age, marital status and parity were the
strongest determinants of HPV prevalence in our study.
As in other studies [10,12,26,27,33], we found that nul-
liparous woman had a higher frequency of HPV DNA
than parous women; nevertheless, there was no clear
trend according to the number of pregnancies.
Part of the variation in HPV prevalence by age in this
population is plausibly related to changes in sexual
behaviour of study women and their sexual partners,
depending on ageing itself and on birth cohort. The sim-
ilarity in HPV prevalence in nulliparous married women
and single women below age 45 years suggests that sex-
ual habits among women or their husbands in Turin
change after the birth of the first child as well as after
marriage. However, this does not rule out a role for
age-related factors other than HPV exposure, such as
acquired immunity. We also observed some reduction
in HPV prevalence with increasing age among married
parous women. Unfortunately, it was not possible to as-
sess the effect of sexual behaviour directly, as we did not
collect information on sexual habits: this is the most rel-
evant limitation of the present study. In a study among
women from a minority population in inner New York
City, who were tested by Southern blot hybridisa-
tion (overall HPV prevalence = 19.8%), the inverse
Table 2
Prevalence ORs of human papillomavirus (HPV) infection and corresponding 95% CI for age and selected characteristics. Turin, Italy, 2002
Characteristic HPV HPV+ (%) Age-adjusted OR (95% CI)a
Age (years)
25–29 100 15 (13.04) 1
30–34 95 15 (13.64) 1.05 (0.49–2.27)
35–39 99 16 (13.91) 1.08 (0.51–2.30)
40–44 100 13 (11.50) 0.87 (0.39–1.92)
45–49 108 6 (5.26) 0.37 (0.14–0.99)
50–54 108 7 (6.09) 0.47 (0.17–1.10)
55–59 105 9 (7.89) 0.57 (0.24–1.37)
60–64 112 3 (2.61) 0.18 (0.05–0.64)
65–70 97 5 (4.90) 0.34 (0.12–0.98)
Education
University degree 61 12 (16.44) 1.91 (0.81–4.51)
Secondary or high school 561 56 (9.08) 0.95 (0.50–1.83)
Primary school (5 years) 258 16 (5.84) 1
None 44 5 (10.20) 1.44 (0.49–4.27)
Marital status
Married 684 53 (7.19) 1
Single (never married) 145 29 (16.67) 2.23 (1.28–3.89)
Widowed 62 4 (6.06) 1.43 (0.46–4.46)
Divorced 33 3 (8.33) 1.41 (0.41–4.88)
Husbands educationb
University degree 45 2 (4.26) 1.00 (0.20–4.96)
Secondary or high school 406 35 (7.94) 1.91 (0.84–4.34)
Elementary school 192 8 (4.00) 1
None 30 4 (11.76) 3.02 (0.83–10.93)
Age at marriage (years)
<20 79 8 (9.20) 1
20–24 340 28 (7.61) 0.81 (0.39–1.69)
25–29 214 11 (4.89) 0.47 (0.19– 1.14)
P 30 113 10 (8.13) 0.82 (0.33–2.03)
Linear trend v21df ¼ 0:07; P ¼ 0:79
Age at first birth (years)
< 20 78 13 (14.29) 1
20–24 268 22 (7.59) 0.50 (0.24–1.06)
25–29 221 9 (3.91) 0.25 (0.10–0.61)
P 30 107 5 (4.46) 0.28 (0.10–0.84)
Linear trend v21df ¼ 7:12; P ¼ 0:0076
Number of children
Nulliparous 250 40 (13.79) 1
Parous (total) 674 49 (6.78) 0.49 (0.31-0.78)
1 child 256 23 (8.24) 0.58 (0.33-1.02)
2 children 303 18 (5.61) 0.40 (0.22–0.74)
P 3 children 115 8 (6.50) 0.48 (0.21–1.09)
Current oral contraceptive use
Yes 94 16 (14.55) 1.36 (0.73–2.52)
No 830 73 (8.08) 1
Only married women included for husbands education or occupation; only parous women included for information on children; only married or
widowed women included for age at marriage.
OR, Odds Ratio; 95% CI, 95% Confidence Interval.
a Adjusted for age (5-year groups).
b Information missing for 15 women.
302 G. Ronco et al. / European Journal of Cancer 41 (2005) 297–305relationship between age and HPV prevalence persisted
after adjustment for sexual behaviour, and sexual habits
had a limited effect within age strata [34]. The role of ac-quired immunity in different populations can be ex-
pected to vary according to the frequency of HPV
infection.
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male population of Turin, as we sampled women partic-
ipating in the organised cervical screening programme,
to which all women between 25 and 64 years are actively
invited every 3 years. Approximately 35% of the women
invited for screening during the study period accepted.
This corresponds to the compliance to invitation previ-
ously observed [16]. However overall coverage in the
Turin population is about 75% as a result of both spon-
taneous and organised screening [16]. In a previous
study of the factors associated with attendance for
screening in Turin [17], we found no significant associa-
tion between participation in the screening programme
and education, marital status or place of birth. In order
to make the present study population more representa-
tive of that of Turin, we included in each age group a
proportion of women who had never been screened be-
fore. We obtained samples from almost 90% of the wo-
men attending the screening programme during the
study period, and only a small proportion of samples
(1.2%) were inadequate for HPV testing. For HPV
DNA detection and typing, we applied a highly sensitive
PCR-based method that was used in most other IARC
surveys [6,9–12,24], thereby improving comparability
with the results from other countries. However, Turin
is an industrial city in North-western Italy, and there-
fore our HPV findings cannot be considered representa-
tive of those in other parts of Italy where no information
is yet available. Indeed, the detection rate of cervical
intraepithelial lesions varies widely in different areas of
Italy [35]. This suggests that HPV prevalence may vary
as well.
In conclusion, our study of the female population of
Turin showed a high HPV prevalence compared with
other southern European populations. In particular,
the relatively high prevalence of HPV infection in all co-
horts of women born after 1960 emphasises the impor-
tance of strengthening screening efforts to avoid a
future increase in cervical cancer.Conflict of interest statement
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